

Special Issue

Molecular Biomarkers of Pulmonary Diseases

Message from the Guest Editor

In this Special Issue, we invite authors to discuss the epidemiology and genetic, epigenetic, and proteomic background of common pulmonary diseases, especially those related to the chronic inflammation and development of pulmonary malignancies, namely, pneumonia, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis. We welcome reviews, mini-reviews, new methods, and original research articles. Topics of interest include the following: (a) The role of genetic, epigenetic, and proteomic specificities in pulmonary disease development and progression and its potential clinical implications for diagnosis, prognosis, and the prediction of therapeutic efficacies and outcomes; (b) The discovery of new molecular biomarkers to monitor the treatment response and early detection of disease and the identification of mechanisms of response to therapy; (c) Clinical trials related to different pulmonary diseases.

Guest Editor

Dr. Jelena Knezevic
Institute Ruder Boskovic, 10000 Zagreb, Croatia

Deadline for manuscript submissions

closed (26 February 2021)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/40467

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))